VYNE Therapeutics Inc. (VYNE): Price and Financial Metrics


VYNE Therapeutics Inc. (VYNE): $0.26

0.01 (+5.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VYNE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VYNE Stock Summary

  • For VYNE, its debt to operating expenses ratio is greater than that reported by just 0.48% of US equities we're observing.
  • With a year-over-year growth in debt of -100%, VYNE THERAPEUTICS INC's debt growth rate surpasses just 0% of about US stocks.
  • As for revenue growth, note that VYNE's revenue has grown -83.5% over the past 12 months; that beats the revenue growth of merely 1.7% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to VYNE THERAPEUTICS INC are GTHX, SMTC, ACVA, EYEN, and FORM.
  • VYNE's SEC filings can be seen here. And to visit VYNE THERAPEUTICS INC's official web site, go to www.menlotherapeutics.com.

VYNE Valuation Summary

  • In comparison to the median Healthcare stock, VYNE's price/sales ratio is 0% higher, now standing at 5.1.
  • VYNE's price/earnings ratio has moved up 43.1 over the prior 61 months.

Below are key valuation metrics over time for VYNE.

Stock Date P/S P/B P/E EV/EBIT
VYNE 2023-01-30 5.1 0.4 -0.6 0.8
VYNE 2023-01-27 5.4 0.4 -0.6 0.8
VYNE 2023-01-26 5.0 0.3 -0.6 0.9
VYNE 2023-01-25 4.8 0.3 -0.5 0.9
VYNE 2023-01-24 4.7 0.3 -0.5 0.9
VYNE 2023-01-23 4.8 0.3 -0.5 0.9

VYNE Growth Metrics

    The 5 year net income to common stockholders growth rate now stands at -226.95%.
  • The 4 year revenue growth rate now stands at -61.81%.
  • Its 3 year price growth rate is now at -98.67%.
Over the past 43 months, VYNE's revenue has gone down $7,380,000.

The table below shows VYNE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 2.763 -35.343 -24.835
2022-06-30 6.682 -45.759 -36.661
2022-03-31 10.814 -53.791 -48.109
2021-12-31 14.755 -56.367 -73.329
2021-09-30 16.749 -71.724 -84.94
2021-06-30 15.932 -77.82 -88.369

VYNE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VYNE has a Quality Grade of D, ranking ahead of 14.91% of graded US stocks.
  • VYNE's asset turnover comes in at 0.132 -- ranking 235th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows VYNE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.132 0.856 -2.324
2021-03-31 0.194 0.926 -5.086
2020-12-31 0.170 0.934 -4.672
2020-09-30 0.140 0.949 -4.901
2020-06-30 0.115 0.964 -4.606
2020-03-31 0.016 0.845 -1.853

VYNE Price Target

For more insight on analysts targets of VYNE, see our VYNE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.00 Average Broker Recommendation 1.58 (Moderate Buy)

VYNE Stock Price Chart Interactive Chart >

Price chart for VYNE

VYNE Price/Volume Stats

Current price $0.26 52-week high $0.79
Prev. close $0.25 52-week low $0.11
Day low $0.24 Volume 348,300
Day high $0.26 Avg. volume 3,306,415
50-day MA $0.21 Dividend yield N/A
200-day MA $0.32 Market Cap 15.09M

VYNE Therapeutics Inc. (VYNE) Company Bio


VYNE Therapeutics Inc. operates as a clinical stage bio-pharmaceutical company. The Company develops medicines and therapies for the treatment of chronic pruritus and cough. VYNE Therapeutics serves customers worldwide.


VYNE Latest News Stream


Event/Time News Detail
Loading, please wait...

VYNE Latest Social Stream


Loading social stream, please wait...

View Full VYNE Social Stream

Latest VYNE News From Around the Web

Below are the latest news stories about VYNE THERAPEUTICS INC that investors may wish to consider to help them evaluate VYNE as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday!

William White on InvestorPlace | January 10, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!

William White on InvestorPlace | January 9, 2023

VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

First patient dosed follows swiftly from IND clearance and enrollment of first healthy volunteers in Phase 1a portion of study in November Topline data expected in 1H 2023 BRIDGEWATER, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the first vitiligo patient has been dosed i

Yahoo | January 9, 2023

VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event

BRIDGEWATER, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that management is scheduled to participate at the LifeSci Partners 12th Annual Corporate Access Event being held during the week of the J.P. Morgan Healthcare Conference, in San Francisco, CA and will be available for o

Yahoo | December 12, 2022

VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform

Newly issued patent expires in 2040BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that GB Patent No. 2597228 entitled “Compounds Comprising N-Methyl-2-Pyridone, And Pharmaceutically Acceptable Salts” has been granted by the United Kingdom’s Intellectual Property Offi

Yahoo | December 7, 2022

Read More 'VYNE' Stories Here

VYNE Price Returns

1-mo N/A
3-mo -4.73%
6-mo -37.36%
1-year -58.07%
3-year -98.59%
5-year N/A
YTD 73.33%
2022 -85.29%
2021 -83.86%
2020 -65.95%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7651 seconds.